On A Roll With Otezla: Can New Orals And Injectables Crack Psoriasis?
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
New drugs for psoriasis and psoriatic arthritis have been in the spotlight recently, with new approvals and full pivotal data releases at the recent American Academy of Dermatology meeting. But how the drugs can make inroads in a safety- and cost-cautious market that will soon feature biosimilars remains to be seen.
You may also be interested in...
Celgene Prices Psoriatic Arthritis Drug Otezla At A Discount, But Higher Than Expected
FDA’s approval of oral apremilast paves the way for the company to establish itself in a range of inflammatory conditions.
IL-17: Pushing The Limits Of A Drug Target
A series of recent and anticipated events is drawing attention to interleukin-17 and related cytokines – a set of immunological drug targets of long-standing interest to large and small companies. The current crop of big-company candidates are biologics and may prove too harsh for all but the most severe immunological conditions, leaving room for start-ups developing small molecules.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.